Haemonetics Corp (HAE)
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.
- Symbol
- HAE
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Medical Devices
- Market cap
- $4.86B
- 52 week range
- 47.32 - 110.45
Valuation
- Share price
- $106.82 (close of 2026-09-23)
- P/E (TTM)
- 51.36x
- Price to book
- 5.80x
- Price to free cash flow
- 16.68x
- Enterprise value
- $5.81B
- Book value per share
- $18.41
Price performance
| Period | Change |
|---|
| 1 day | -1.76% |
| 5 days | +0.58% |
| 1 month | -1.82% |
| 3 months | +46.77% |
| 6 months | +82.72% |
| Year to date | +33.28% |
| 1 year | +110.90% |
| 3 years | +18.62% |
| 5 years | +53.41% |
| 10 years | +185.01% |
| All time | +1698.32% |
Profitability and growth
- Return on equity
- 12.22%
- Return on invested capital
- 7.10%
- Return on assets
- 4.06%
- Return on capital employed
- 7.42%
- Gross margin
- 59.04%
- Net margin
- 7.29%
- EBITDA margin
- 20.12%
- Revenue growth
- -1.97%
- Net income growth
- -41.97%
- Free cash flow growth
- 82.83%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 6.00%
- Current ratio
- 3.08x
- Net debt to EBITDA
- 3.52x
Latest reported year
- Period end
- 2026-03-28
- Fiscal year
- 2026
- Revenue
- $1.33B
- Cost of revenue
- $546.44M
- Gross profit
- $787.59M
- EBITDA
- $268.45M
- Net income
- $97.31M
- Earnings per share
- $2.06
- Research and development
- $59.77M
- Shares outstanding
- 47.18M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2026-03-28 | $1.33B | $787.59M | $97.31M | $2.06 |
| 2025-03-29 | $1.36B | $748.96M | $167.68M | $3.33 |
| 2024-03-30 | $1.31B | $691.55M | $117.56M | $2.32 |
| 2023-04-01 | $1.17B | $615.10M | $115.40M | $2.27 |
| 2022-04-02 | $993.20M | $505.50M | $43.38M | $0.85 |
| 2021-04-03 | $870.46M | $397.84M | $79.47M | $1.57 |
| 2020-03-28 | $988.48M | $484.51M | $76.53M | $1.51 |
| 2019-03-30 | $967.58M | $417.54M | $55.02M | $1.07 |
| 2018-03-31 | $903.92M | $411.91M | $45.57M | $0.86 |
| 2017-04-01 | $886.12M | $378.49M | $-26.27M | $-0.51 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2026-03-28 | 59.04% | 7.29% | 12.22% | 7.10% |
| 2025-03-29 | 55.04% | 12.32% | 20.43% | 10.20% |
| 2024-03-30 | 52.83% | 8.98% | 12.25% | 8.22% |
| 2023-04-01 | 52.63% | 9.87% | 14.11% | 10.01% |
| 2022-04-02 | 50.90% | 4.37% | 5.79% | 4.56% |
| 2021-04-03 | 45.70% | 9.13% | 10.86% | 6.81% |
| 2020-03-28 | 49.02% | 7.74% | 13.03% | 10.40% |
| 2019-03-30 | 43.15% | 5.69% | 8.24% | 7.65% |
| 2018-03-31 | 45.57% | 5.04% | 6.06% | 5.10% |
| 2017-04-01 | 42.71% | -2.96% | -3.55% | -1.99% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2026-03-28 | $245.44M | $1.22B |
| 2025-03-29 | $306.76M | $921.23M |
| 2024-03-30 | $178.80M | $797.56M |
| 2023-04-01 | $284.47M | $754.10M |
| 2022-04-02 | $259.50M | $559.44M |
| 2021-04-03 | $192.31M | $690.59M |
| 2020-03-28 | $137.31M | $305.51M |
| 2019-03-30 | $169.35M | $322.45M |
| 2018-03-31 | $180.17M | $59.42M |
| 2017-04-01 | $139.56M | $253.63M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2026-03-28 | $260.44M | $33.83M |
| 2025-03-29 | $142.45M | $29.64M |
| 2024-03-30 | $143.63M | $28.33M |
| 2023-04-01 | $81.73M | $25.58M |
| 2022-04-02 | $75.75M | $24.36M |
| 2021-04-03 | $71.77M | $25.52M |
| 2020-03-28 | $109.46M | $20.45M |
| 2019-03-30 | $40.32M | $17.19M |
| 2018-03-31 | $145.55M | $13.03M |
| 2017-04-01 | $83.60M | $9.15M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-05
- Consensus EPS estimate
- $1.30
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-06 | Jun/2026 | $1.07 |
| 2026-05-07 | - | - |
| 2026-02-05 | - | - |
| 2025-11-06 | - | - |
| 2025-08-07 | - | - |
| 2025-05-08 | - | - |
| 2025-02-06 | - | - |
| 2024-11-07 | - | - |
Filings and sources
- Company website
- haemonetics.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Abbott Laboratories (ABT) · Medtronic plc (MDT) · Stryker Corp (SYK) · Boston Scientific Corp (BSX) · Edwards Lifesciences Corp (EW) · Dexcom Inc (DXCM) · STERIS plc (STE) · Zimmer Biomet Holdings, Inc. (ZBH)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades